Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 20/20 | 0.86 |
| ▸ | HDAC1 | Q13547 | 19/20 | 0.86 |
| ▸ | HDAC2 | Q92769 | 19/20 | 0.86 |
| ▸ | HDAC6 | Q9UBN7 | 15/20 | 0.86 |
| ▸ | HDAC8 | Q9BY41 | 12/20 | 0.86 |
| ▸ | NCOR2 | Q9Y618 | 9/20 | 0.86 |
| ▸ | HDAC10 | Q969S8 | 7/20 | 0.86 |
| ▸ | HDAC11 | Q96DB2 | 3/20 | 0.86 |
| ▸ | UBA1 | P22314 | 1/20 | 0.73 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.73 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.73 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12610998 | 1.00 | HDAC3 (0.86) | HDAC3HDAC1HDAC2HDAC6HDAC8 | |
| SCHEMBL10315069 | 0.94 | HDAC3 (0.86) | HDAC3HDAC1HDAC2HDAC6HDAC8 | |
| SCHEMBL12651856 | 0.93 | HDAC3 (0.88) | HDAC3HDAC1HDAC2HDAC6HDAC8 | |
| SCHEMBL12611184 | 0.93 | HDAC3 (0.88) | HDAC3HDAC1HDAC2HDAC6HDAC8 | |
| SCHEMBL17305526 | 0.93 | HDAC3 (0.86) | HDAC3HDAC1HDAC2HDAC6HDAC8 | |
| Largazole Thiol SCHEMBL15827016 | 0.93 | HDAC3 (1.00) | HDAC3HDAC1HDAC2HDAC6HDAC8 | |
| SCHEMBL21586611 | 0.93 | HDAC3 (0.86) | HDAC3HDAC1HDAC2HDAC6HDAC8 | |
| SCHEMBL22810153 | 0.93 | HDAC3 (0.86) | HDAC3HDAC1HDAC2HDAC6HDAC8 | |
| Largazole Thiol SCHEMBL7994520 | 0.93 | HDAC3 (1.00) | HDAC3HDAC1HDAC2HDAC6HDAC8 | |
| Largazole Thiol SCHEMBL72077 | 0.93 | HDAC3 (1.00) | HDAC3HDAC1HDAC2HDAC6HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9492434-B2 | Combination compositions and methods of treatment | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2016-11-15 | — | — | US | disclosed |
| US-20150210718-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF TREATMENT | UNIV FLORIDA (US) | 2015-07-30 | — | — | US | disclosed |
| US-20140323450-A1 | COMBINATION COMPOSITIONS AND METHODS OF TREATMENT | University of Florida Research Founation (US) | 2014-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140323450-A1 | COMBINATION COMPOSITIONS AND METHODS OF TREATMENT | NFATC1, MCL1, CKMT1A; CKMT1B | HDAC3 97/4885HDAC1 120/4885HDAC2 529/4885 |
| US-20150210718-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF TREATMENT | HDAC1, HDAC11, HDAC3 | HDAC3 3/4885HDAC1 1/4885HDAC2 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.